QuidelOrtho Demonstrates Automated, Sample-To-Result, Multiplex RT-PCR Testing Platform at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 08 Feb 2023

Image: QuidelOrtho is demonstrating how to improve workflow and respond more flexibly and quickly to patient needs (Photo courtesy of QuidelOrtho)

At Medlab Middle East 2023, QuidelOrtho Corporation (San Diego, CA, USA) is showcasing for the first time the benefits of the combined organization’s consolidated portfolio of world-class technologies and platforms, through expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening, and point-of-care diagnostics offerings.

At the QuidelOrtho booth, the focus is on the Savanna automated, sample-to-result, multiplex RT-PCR testing platform that performs real-time Polymerization Chain Reaction (PCR) tests by using the Savanna instrument and Savanna assay cartridges. This evolutionary multiplex molecular platform enables professional customers to analyze up to 12 pathogens or targets, plus controls, from a single assay run in less than 30 minutes. After inserting the assay cartridge, the instrument performs sample and reagent preparation, nucleic acid extraction and amplification, real-time detection of RNA or DNA target sequence, and qualitative or quantitative result interpretation from a variety of sample types. The Savanna system is intended to aid in the diagnosis of the related diseases.

QuidelOrtho is also demonstrating the Savanna RVP4 Assay (Respiratory Viral Panel-4), a rapid, multiplexed nucleic acid test intended for use with the Savanna instrument for the simultaneous qualitative detection and differentiation of influenza A (Flu A), influenza B (Flu B), respiratory syncytial virus (RSV), and SARS-CoV-2 RNA isolated from human nasal or nasopharyngeal swabs in media obtained from patients with signs and symptoms of respiratory tract infection. The in vitro diagnostic test is intended to aid in the differential diagnosis of infections with these viruses. The Savanna RVP4 Assay comes in a fully integrated cartridge that is stable at room temperature.

Related Links:
QuidelOrtho Corporation

Visit expo >

Platinum Member

Automated Coagulation Analyzer

Hemolumi H6

βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®

New

Automated Immunoassay Analyzer

SuperFlex™

Gold Member

Fully-auto Specific Protein (Nephelometry) Analyzer

PA240

Latest Medlab 2023 News

Channels

Clinical Chemistry

view channel

Noninvasive Tests Offer Alternatives to Biopsy for Assessing Advanced Liver Scarring

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to one in three adults worldwide and as many as seven in 10 people with obesity or type 2 diabetes. Its more severe form, metabolic... Read more

Molecular Diagnostics

view channel

AI-Supported Approach May Improve Cervical Cancer Screening in Low-Resource Settings

Cervical cancer screening coverage often remains below 15% in low- and middle-income countries. Limited accuracy of visual inspection with acetic acid, together with uneven access to high-quality human... Read more

Image: Overview of the neural network architecture and training. (Stefan, S., Amann, A.S., Smith, K.S. et al. AI-based precision prognostics and therapy personalization for childhood brain tumors. Nature Genetics (2026). https://doi.org/10.1038/s41588-026-02815-4)

Molecular AI Model Refines Risk Prediction in Pediatric Brain Tumors

Choosing treatment for a child with a malignant brain tumor requires balancing cancer control against lasting effects on learning, development, and quality of life. This balance is complicated by differences... Read more

Multiplex PCR Panel Gains FDA Clearance for Viral Hemorrhagic Fever Detection

Viral hemorrhagic fevers caused by Ebola, Marburg, Lassa, and Crimean-Congo hemorrhagic fever viruses can initially resemble other febrile illnesses, making early diagnosis difficult. As of October 31,... Read more

$Image: These images show breast tumors in a new preclinical model developed by Garvan researchers. The cells carry a fluorescent sensor that lights up blue/green when CDK1—the protein \'engine\' cells need to divide—is switched on. Using it, the team watched CDK1 activity rise as tumors became invasive and stay high in tumors that kept growing despite treatment. (Image Credit: Dr. Max Nobis / Garvan Institute)$